Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M52.5Revenue (TTM) $M0.0Net Margin (%)-53,658.5Altman Z-Score-25.1
Enterprise Value $M40.0EPS (TTM) $-0.9Operating Margin %-53,658.5Piotroski F-Score3
P/E(ttm)--Beneish M-Score1.3Pre-tax Margin (%)-53,658.5Higher ROA y-yN
Price/Book5.010-y EBITDA Growth Rate %-16.3Quick Ratio5.6Cash flow > EarningsY
Price/Sales1,0805-y EBITDA Growth Rate %14.1Current Ratio5.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-100.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-113.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M24.3ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RPRXJohn Paulson 2014-12-31 Sold Out -0.04%$6.02 - $10.69
($8.49)
$ 2.16-75%Sold Out0
RPRXJohn Paulson 2014-09-30 Buy 0.04%$8.77 - $22.16
($14.84)
$ 2.16-85%New holding1,000,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RPRX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PODOLSKI JOSEPHPresident and CEO 2016-02-18Buy10,000$0.93132.26view
PODOLSKI JOSEPHPresident and CEO 2016-01-07Buy11,677$1.1883.05view
Anderson KatherineCFO 2014-11-12Buy3,500$9.41-77.05view
PODOLSKI JOSEPHPresident and CEO 2014-11-12Buy4,700$9.42-77.07view
Masterson Nola EDirector 2014-09-15Buy200$14.34-84.94view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.91-84.47view
Anderson KatherineCFO 2014-08-14Buy2,000$13.85-84.4view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-85.57view
PODOLSKI JOSEPHPresident and CEO 2013-10-25Buy3,000$18.03-88.02view
Anderson KatherineCFO 2013-10-25Buy1,000$17.9-87.93view

Quarterly/Annual Reports about RPRX:

News about RPRX:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 
Repros Therapeutics Inc. (RPRX) CEO Joseph Podolski buys 4,000 Shares Mar 05 2009 
Weekly CEO Buys Highlight: Medtox Scientific Inc., Provident Bankshares Corp., Escalade Inc., Repros Apr 25 2008 

More From Other Websites
Repros Seeks EU Approval for Secondary Hypogonadism Drug Sep 13 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Sep 12 2016
Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the... Sep 12 2016
Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the... Sep 12 2016
Why Twitter, AMD and 2 Other Stocks Are in the Red Today, While Repros is Surging Sep 08 2016
Here’s What Latest Data Could Mean For Repros Therapeutics Inc (RPRX) Sep 08 2016
Why Repros Is Rising Sep 08 2016
Repros Therapeutics' (RPRX) Proellex Positive in Phase II Sep 08 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Sep 07 2016
Repros Provides Phase 2 Results Showing Positive Outcomes for Oral Proellex® in Women With Moderate... Sep 07 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Aug 18 2016
REPROS THERAPEUTICS INC. Financials Aug 17 2016
Repros Presents 6-Month Interim Data on Enclomiphene Aug 16 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events Aug 15 2016
Repros Provides Six Month Interim Results for Enclomiphene Study in Obese Secondary Hypogonadal Men Aug 15 2016
Repros (RPRX) Q2 Loss Narrower Y/Y, Focus on Pipeline Aug 10 2016
REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 09 2016
Repros Therapeutics Inc.® Reports Second Quarter 2016 Financial Results Aug 09 2016
Repros Therapeutics reports 2Q loss Aug 09 2016
Repros Therapeutics reports 2Q loss Aug 09 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)